Ventripoint Diagnostics Ltd. Signs Commercial Agreement with LG Consulting Solutions to Support VMS+ Deployment in Northern California

(TheNewswire)

Toronto, Ontario – TheNewswire - March 3,2026 – Ventripoint Diagnostics Ltd.(“Ventripoint” or the “Corporation”,TSXV:VPT) today announced the signing of aMemorandum of Understanding and consulting agreement with LGConsulting Solutions to support commercialization and deployment ofthe VMS+™ system in the Northern California region.

Under the agreement, LG Consulting Solutions willprovide economic analysis, clinical implementation support, and healthsystem business case development to assist hospitals and cardiacprograms in adopting Ventripoint’s VMS+™ technology. Thecollaboration will focus on demonstrating the economic and clinicalvalue of AI-enhanced echocardiography imaging and workflow integrationacross healthcare systems in the region, including Sacramento and SanFrancisco.

As part of the agreement, LG Consulting Solutions ispurchasing a VMS+™ system for deployment as a demonstration andimplementation platform to support hospital engagement, cliniciantraining, and economic value assessments within targeted healthcareinstitutions.

The agreement includes consulting services related tooutcomes evaluation, implementation planning, and ongoing operationalsupport. The collaboration is designed to help healthcare providersbetter understand the clinical and economic impact of cardiacassessment using the VMS+™ system.

“Economic and operational clarity are critical toaccelerating the adoption of new medical technologies,” said HughMacNaught, President and CEO of Ventripoint. “This collaborationwill help hospitals clearly evaluate how VMS+™ can improve cardiaccare pathways, enhance clinical insight into cardiac function, andsupport better patient care while delivering measurable value tohealthcare systems.”

Lori Gallian, Principal of LG Consulting, added:

“Healthcare systems increasingly require clearclinical and economic evidence before adopting new technologies.Through this collaboration, we will work directly with cardiacprograms to develop practical implementation strategies anddemonstrate how VMS+ ™can deliver both clinical and operationalbenefits.”

The agreement also includes the potential for revenuesharing related to 3D echocardiography processing services associatedwith accounts supported by the consulting engagement.

Northern California represents an important market forVentripoint given its concentration of leading cardiac centers andhealthcare systems focused on improving cardiovascular outcomes andoperational efficiency.

About LG Consulting Solutions

LG Consulting Solutions brings nearly a decade ofestablished relationships and on-the-ground experience within thehospital networks they serve. The consultancy's approachis built on something the healthcare industrydoesn't always slow down for - listening. By genuinely hearingwhat clinicians need, how they work, and what earns their trust, LGConsulting Solutions bridges the gap between innovative technology andreal-world clinical adoption. Their work is rooted in connectionfirst, integration second, and the belief that the best outcomeshappen when healthcare providers feel heard before they're askedto change.

About Ventripoint DiagnosticsLtd.

Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary knowledge-based reconstruction technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all of Ventripoint's productsthat guide our future developments. In addition, VMS+ is versatile andcan be used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.

For further information, pleasecontact:

Hugh MacNaught

hmacnaught@ventripoint.com

604-671-4201

Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' andsimilar expressions are intended to identify forward-lookinginformation or statements. The forward-looking statements andinformation are based on certain key expectations and assumptions madeby the Corporation. Although the Corporation believes that theexpectations and assumptions on which such forward-looking statementsand information are based are reasonable, undue reliance should not beplaced on the forward-looking statements and information because theCorporation can give no assurance that they will prove to becorrect.

Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results coulddiffer materially from those currentlyanticipated due to a number of factors and risks. Factors which couldmaterially affect such forward-looking information are described inthe risk factors in the Corporation's most recent annualmanagement's discussion and analysis that is available on theCorporation's profile on SEDAR+ at www.sedarplus.ca. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Corporation undertakes no obligation to update publiclyor revise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.

Copyright (c) 2026 TheNewswire - All rights reserved.